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Abstract
Background—Understanding more about circumstances in which patients receive an opioid use 
disorder (OUD) diagnosis might illuminate opportunities for intervention and ultimately prevent 
opioid overdoses. This study aimed to describe patient and clinical characteristics of hospital 
discharges documenting OUD among patients not being treated for opioid overdose, 
detoxification, or rehabilitation.
Methods—We assessed patient, payer, and clinical characteristics of nationally-representative 
2011–2015 National Inpatient Sample discharges documenting OUD, excluding opioid overdose, 
detoxification, and rehabilitation. Discharges were clinically classified by Diagnostic Related 
Group (DRG) for analysis.
Results—Annual discharges grew 38%, from 347,137 (2011) to 478,260 (2015), totaling 2 
million discharges during the study period. The annual discharge rate increased among all racial/
ethnic groups, but was highest among the non-Hispanic black population until 2015, when non-
Hispanic whites had a slightly higher rate (164 versus 162 per 100,000 population). Female 
patients and Medicaid and Medicare as primary payer accounted for an increasing annual 
proportion of discharges. Just 14 DRGs accounted for nearly 50% of discharges over the study 
period. The most prevalent primary treatment received during OUD inpatient stays was for 
psychoses (DRG 885; 16% of discharges) and drug and alcohol abuse or dependence symptoms 
(including withdrawal) or (non-opioid) poisoning (DRG 894, 897, 917, 918; 12% of discharges).
Conclusions—Now nearly half a million yearly US hospital discharges for a range of primary 
treatment include patients’ diagnosis of OUD without opioid overdose, detoxification, or 
rehabilitation services. Inpatient stays present an important opportunity to link OUD patients to 
treatment to reduce opioid-related morbidity and mortality.
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1. Introduction
The number of US hospital discharges and emergency department visits documenting opioid 
abuse, dependence, or poisoning (overdose) combined was more than twice as high in 2014 
compared to 1997 (Tedesco et al., 2017). Opioid-related overdose deaths nearly tripled 
during approximately the same period, reaching 42,249 deaths in 2016 (Centers for Disease 
Control and Prevention National Center for Health Statistics, 2016).
To reduce opioid overdoses, prevention efforts must reach at-risk patients. To date, we are 
not aware of reporting that quantifies US prevalence of opioid use disorder (OUD) separate 
from overdoses using health services data, nor analysis of health services contacts (e.g., 
inpatient stay) during which patients were diagnosed with OUD in the absence of opioid 
overdose (Guy Jr., Pasalic, & Zhang, 2018; Heslin et al., 2017; Hsu, McCarthy, Stevens, & 
Mukamal, 2017; Tedesco et al., 2017; Weiss et al., 2016). Using the most recent five years of 
US national hospital discharge data, this brief report aimed to describe patient and clinical 
characteristics of discharges during which providers documented OUD among patients who 
were not treated for opioid overdose, opioid detoxification, or opioid rehabilitation during 
the inpatient stay.
2. Material and methods
This study used publicly available data and no human subjects. Using 2011–2015 (most 
recent) survey-weighted annual national estimates of US hospital discharges (Healthcare 
Cost and Utilization Project National Inpatient Sample [HCUP NIS]), we identified 
discharges documenting any diagnosis (i.e., primary or non-primary) of opioid abuse or 
dependence, excluding discharges with any diagnosis indicating opioid overdose or any 
procedure code or Diagnosis Related Group (DRG) code indicating drug detoxification or 
drug rehabilitation services (see Table 1 notes for applicable International Classification of 
Diseases, Ninth Revision or Tenth Revision, Clinical Modification [ICD-9/10-CM] and 
DRG codes). Standard HCUP NIS survey weighting and Census population data made the 
discharges sample representative of all US discharges for age-adjusted estimates (Centers for 
Disease Control and Prevention, 2017).
We report selected patient (e.g., sex, average age, race/ethnicity), hospital stay (e.g., length 
of stay), and payer characteristics among analysis discharges. To summarize clinical 
characteristics of the analysis discharges, we classified discharges by DRG (n > 700 
categories) and ranked discharges by DRG prevalence, reporting DRG categories with > 1% 
of discharges over the study period. DRG classifies patients based on clinical similarity and 
in terms of their consumption of hospital resources (US Centers for Medicaid and Medicare, 
2016). Each discharge is identified by a single DRG, which typically is the basis for the 
hospital’s payment. We further classified discharges for drug-related DRGs by primary 
ICD-9/10-CM diagnosis (n > 14,000 ICD-9-CM and n > 69,000 ICD-10 categories) and 
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reported ICD-9/10-CM categories with > 5% of discharges per drug-related DRG over the 
study period.
3. Study results
The survey-weighted number of discharges annually documenting patient OUD without 
opioid overdose, detoxification, or rehabilitation services increased by 38% over the study 
period (from 347,137 in 2011 to 478,260 in 2015) (Table 1). Diagnosis codes for opioid 
abuse or dependence appeared in the non-primary diagnosis position in the discharge record 
for over 98% of analysis discharges (data not shown).
3.1. Patient, hospital stay, and payer characteristics
Average patient age increased slightly (from 43.5 years old in 2011 to 45.1 in 2015) over the 
study period, as did average length of hospital stay (from 5.5 days in 2011 to 5.7 in 2015). 
Women accounted for a modestly higher proportion of these discharges at the end of the 
study period (49% in 2011 versus 50% in 2015). Medicaid and Medicare were the primary 
payers for 35% and 25% of discharges in 2011, respectively, and 44% and 29% of 
discharges in 2015. Self-pay discharges decreased from 14% in 2011 to 7% in 2015.
The age-adjusted population discharge rate among non-Hispanic Asian/Pacific Islander 
patients was 78% higher (15.3 versus 8.6 per 100,000 population) in 2015 versus 2011, 48% 
higher (164.1 versus 110.6) among non-Hispanic whites, 25% higher (70.2 versus 56.2) 
among Hispanics, and 21% higher (161.9 versus 134.2) among non-Hispanic blacks (Table 
1). The 2011 rate among non-Hispanic American Indian/Pacific Islanders was not reportable 
based on limited sample size, although the rate was 41% higher (133.7 versus 95.0 per 
100,000) in 2015 versus 2012. From 2011 to 2014, non-Hispanic blacks had the highest 
population discharge rate among all racial/ethnic patient categories, but this rate was not 
statistically significantly greater than non-Hispanic whites, except in 2012. In 2015, for the 
first time during the study period, non-Hispanic whites had a slightly higher—but not 
statistically significant—population discharge rate than non-Hispanic blacks (164.1 versus 
161.9 per 100,000 population).
3.2. Clinical classification by Diagnostic Related Group
The estimated 2,002,257 discharges documenting OUD without opioid overdose, drug 
detoxification, or drug rehabilitation were classified by over 450 different DRGs during the 
study period (data not shown). However, just 14 DRGs each accounted for > 1% of 
discharges during the study period (Table 2). Together those 14 DRGs accounted for nearly 
50% of total discharges during the 5-year study period.
The most prevalent DRG among analysis discharges indicated that primary treatment was 
for psychoses (DRG 885) (Table 2). This DRG appeared on 322,544 (or 16%) analysis 
discharges over the study period. DRGs indicating primary treatment for alcohol or non-
opioid drug abuse or dependence or poisoning appeared on a combined 248,955 (or 12%) 
analysis discharges over the study period (number of discharges by DRG in Table 2: DRG 
894, 897, 917, 918). Among such discharges without poisoning (DRG 897), primary 
diagnoses indicated treatment was frequently for drug (ICD-9-CM 292.0) or alcohol (ICD-9-
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CM 291.81) withdrawal (combined 72,574 discharges) or drug-induced mood disorder 
(ICD-9-CM 292.84) (24,802 discharges). Opioid-type dependence (ICD-9-CM 304.0) was 
also frequently the primary diagnosis among discharges with this DRG (17,925 discharges).
Among discharges with DRGs for alcohol or drug-related poisoning (DRG 917, 918) 
(61,043 discharges), primary ICD diagnoses indicated treatment was for poisoning by a 
variety of non-opioid substances (benzodiazepine-based tranquilizer, aromatic analgesic, 
cocaine, unspecified drug or medicinal substance, unspecified sedative or hypnotic). DRGs 
for cellulitis (DRG 603), antepartum and labor (DRG 765, 775, 781), septicemia (DRG 871, 
872) depressive neuroses (DRG 881), esophagitis, gastroenteritis and miscellaneous 
digestive disorders (DRG 392) and chronic obstructive pulmonary disease (DRG 191) were 
the remaining DRGs that comprised > 1% of analysis discharges during the study period.
4. Discussion
This study described patient, hospital stay, payer, and clinical characteristics of inpatient 
stays during which OUD was documented in the absence of opioid overdose, detoxification, 
or rehabilitation inpatient services. There are three important takeaways from this analysis. 
First, across the US, population survey data indicate that 2.1 million people aged 12 or older 
had OUD in 2016 (Substance Abuse and Mental Health Services Administration, 2017). 
This study’s finding of nearly 500,000 hospital discharges documenting OUD (without 
overdose) in 2015 suggests a high proportion of the US population with OUD is treated in 
inpatient settings annually, highlighting a potentially key opportunity for inpatient service 
providers to link patients to treatment services and prevent overdose.
Second, the rising rate of opioid-related mortality among white, non-Hispanic men has 
received considerable media and research attention (National Public Radio, November 17, 
2017; Song, 2017). However, this study demonstrated that approximately half of hospital 
discharges documenting OUD without overdose in recent years were for female patients and 
that the population rate of such hospital discharges among non-Hispanic blacks was at least 
as high or higher than for white non-Hispanics.
Third, characterizing discharges by DRG (and, in the case of drug-related DRGs, by primary 
ICD diagnosis) illuminated a reasonable degree of commonality among the > 2 million 
analysis discharges over the study period—in that nearly 50% of these discharges were 
billed under just 14 DRGs—and highlighted the co-occurring health challenges associated 
with the opioid overdose epidemic. For example, the high prevalence of cellulitis treatment 
among inpatients with OUD may be linked to rising injection drug use (Binswanger, Kral, 
Bluthenthal, Rybold, & Edlin, 2000). A high number of antepartum and delivery discharges 
noting OUD is consistent with recent research documenting increased prevalence of neonatal 
abstinence syndrome (Ko et al., 2016). The high prevalence of OUD discharges assigned to 
DRG 885 (titled “Psychoses” and including mental health diagnoses such as schizophrenia 
and major depressive disorder) likely reflects the heightened risk of opioid misuse among 
patients with mental health disorders. That diagnoses related to use, dependence, and 
withdrawal from other drugs and alcohol comprised the second largest OUD discharge 
category by DRG illustrates the high co-occurring prevalence of opioid misuse and other 
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substance use disorders. This DRG analysis also highlights a challenge for inpatient service 
providers that endeavor to link OUD patients to treatment services, in that such patients 
appear to attend inpatient settings for a wide variety of primary treatment—meaningful links 
to treatment services would likely therefore require casting a wide net over inpatient 
populations.
This analysis had several limitations. First, the use of administrative medical data for this 
analysis required an assumption that certain ICD-CM codes indicate OUD, which is 
formally defined not by such codes but by a series of symptoms described in the Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition. This study followed physician 
guidance on coding OUD in administrative records indicating the use of ICD-CM codes 
titled “Opioid type dependence” (ICD-9-CM 304.0, ICD-10-CM F11.2) and “Opioid abuse” 
(ICD-CM 305.5 and F11.1), to identify OUD, contingent upon presence of certain patient 
symptoms as observed by the attending clinician (Providers Clinical Support System, 2018). 
The codes used in this study to identify analysis discharges are consistent with recent 
research on opioid abuse that, like this study, examined administrative medical records 
(Paulozzi, Zhou, Jones, Xu, & Florence, 2016).
A second notable limitation is that we do not know how many of these discharges occurred 
among the same patients. Third, we were not able to observe whether patients had 
concurrent outpatient substance abuse treatment. Fourth, this study focused on OUD, 
although increasingly research demonstrates that multiple drug types are responsible for the 
overall increase in US drug-related mortality in recent years, which affects both men and 
women of multiple racial/ethnic groups (Shiels, Freedman, Thomas, & de Gonzalez, 2017). 
Fifth, this study classified discharges by DRG to investigate clinical commonalities. DRG is 
typically the basis for hospital payment and therefore it is possible that DRG designations 
for some discharges prioritized financial, rather than clinical, considerations. Sixth, we did 
not attempt to translate ICD-10 codes (which appeared in three months of this study’s 5-year 
timeline—October-December 2015) to ICD-9-CM codes when presenting the prevalence of 
primary diagnosis codes within drug-related DRG categories; therefore, our presentation of 
discharges by primary ICD codes likely modestly undercounts the prevalence of individual 
primary diagnoses. Seventh, it is possible that psychiatrists—the providers presumed to 
primarily manage inpatients with psychoses DRG designations—are more attuned to 
substance use disorders like OUD. This might bias hospital discharge records for mental 
health stays toward greater documentation of OUD and other substance disorders, which 
may be a contributing explanation of the high prevalence of DRG 885 among discharges 
documenting OUD. Finally, this descriptive study has not attempted to identify reasons for 
the changes observed in terms of number of discharges by patient and payer characteristics.
It was not possible to ascertain whether the increased number of discharges documenting 
OUD fully reflects an expanding affected population or whether some proportion of the 
increase reflects instead greater recognition and documentation of OUD by all providers 
given recent increased attention to opioid overdoses. Owing to social stigma surrounding 
substance abuse, differences in the rate at which patients by race/ethnicity receive an OUD 
diagnosis on a hospital discharge record quite plausibly might be driven by provider bias. 
Notably, the opioid-related mortality rate among non-Hispanic black men and women during 
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2012–2015 was far less than that of non-Hispanic white men and women, although the 
present study has demonstrated a similar or higher population prevalence of hospital 
admissions documenting patient OUD among non-Hispanic blacks during the same period 
(Shiels et al., 2017). Future research with longitudinal medical claims data might investigate 
which patients receive OUD treatment based on patient characteristics and clinical 
circumstances in which OUD is first documented.
Identifying patients with OUD without opioid overdose seems a straightforward way to 
target prevention services, such as meaningful links to substance abuse treatment that may 
ultimate reduce opioid-related morbidity and mortality. But ensuring appropriate and 
successful substance abuse treatment for such patients is undeniably complex. Analysis of 
2010–11 medical claims data indicated that patients with opioid prescriptions and diagnosed 
OUD were substantially more likely to have an opioid overdose than patients with opioid 
prescriptions but no OUD diagnosis (Paulozzi et al., 2016). However, researchers that 
conducted that study also reported opioid prescribing did not change after patients received 
an OUD diagnosis (although researchers were not able to examine which clinicians provided 
the prescriptions before or after the OUD diagnosis) (Paulozzi et al., 2016). Programs to 
treat substance abuse disorders among inpatients have demonstrated success, although 
patients are often discharged without specific plans for treatment services and patient 
follow-up for post-discharge treatment is low (Naeger, Mutter, Ali, Mark, & Hughey, 2016; 
Rosenthal, Karchmer, Theisen-Toupal, Castillo, & Rowley, 2016; Trowbridge et al., 2017).
5. Conclusions
This study comprehensively described patient, hospital stay, payer, and clinical 
characteristics of the hundreds of thousands of US hospital discharges per year that 
document patient OUD without opioid overdose, detoxification, or rehabilitation services. 
Hospital and health systems administrators and public health officials might consider 
whether in their local areas sufficient policies and practices exist, first to treat substance 
abuse disorders among inpatients, and second to effectively link discharged patients to 
continuing treatment services. Further, given the range of primary treatment (observed by 
DRG in this study) dispensed to patients with OUD during hospital stays, it appears 
important to consider whether existing inpatient policies and practices related to drug 
treatment are reaching what appears to be a wide variety of patients diagnosed with OUD.
Abbreviations
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